Full-Time
Confirmed live in the last 24 hours
Biotech startup developing innovative medicines
$217k - $237.5kAnnually
Expert
Newark, NJ, USA + 1 more
More locations: New York, NY, USA
The position requires a minimum of 3 days a week of onsite presence in either California, New York, or New Jersey offices.
Eikon Therapeutics focuses on discovering and developing new medicines in the pharmaceutical industry. The company employs advanced technologies to study biological systems, aiming to identify new drug targets by examining the dynamic aspects of biology rather than just static chemical processes. Their team consists of diverse professionals, including data scientists, chemists, and engineers, which allows them to combine science and engineering to create new therapies that improve and extend life. A key feature of their approach is a proprietary single-molecule tracking (SMT) platform that visualizes protein motion in living cells, enabling them to analyze molecular interactions with high precision. Eikon Therapeutics aims to serve patients with serious diseases by developing effective treatments and generates revenue through the commercialization of these therapies.
Company Size
201-500
Company Stage
Series D
Total Funding
$1.1B
Headquarters
Hayward, California
Founded
2019
Help us improve and share your feedback! Did you find this helpful?
401(k) Company Match
Medical (premiums covered by Eikon at 95%)
Dental Insurance
Vision Insurance
Mental Health Support
Unlimited Paid Time Off
Paid Holidays
Life Insurance
Enhanced Parental Leave
Daily subsidized lunch program
Another significant entity, Soros Capital - managed by Robert Soros, son of the billionaire George Soros - participated in a $350.7 million financing round for Eikon Therapeutics.
Eikon Therapeutics, Inc., a pivotal-stage biotechnology company that integrates advanced engineering with cutting-edge molecular and cell biology to a
Eikon Therapeutics, led by former Merck RD head Roger Perlmutter, raised $350 million, bringing its total funding to $1.1 billion. The funds will support the clinical development of cancer drugs, including an immunotherapy in Phase 3 for melanoma and two PARP inhibitors. The financing round included investors like Lux Capital and Alexandria Venture Investments.
Eikon Therapeutics Inc. has closed a $351 million series D funding round, marking the largest venture capital round of 2025 and the first series D of the year. This funding supports Eikon as it enters phase III in cancer treatment development.
Eikon Therapeutics to present at the 43rd Annual J.P. Morgan Healthcare Conference.